Xencor Inc (XNCR) - News Archive

Xencor s Bold Advances in Oncology: Initial Results on XmAb819 and Future Prospects in Autoimmune Disease In the intricate landscape of oncology and autoimmune disease treatment, Xencor, Inc. (NASDAQ: XNCR), has emerged...

Innovative Landscape in Oncological Therapies: A Focus on XmAb819 in Clear Cell Renal Cell Carcinoma and Xencor s Competitive Position Renal cell carcinoma (RCC) has seen a paradigm shift in treatment strategies over th...

Xencor Inc. has made significant strides in the development of its XmAb drug candidates targeting autoimmune diseases, alongside notable clinical progress in early-stage oncology programs. However, the company s financi...

Xencor, Inc. (NASDAQ: XNCR), a notable clinical-stage biopharmaceutical company based in Pasadena, California, is making significant strides in the development of engineered antibodies. This innovative company is focuse...

Xencor, a leading clinical-stage biopharmaceutical company specializing in engineered antibodies and cytokines, announced in a recent press release that Dane Leone, a seasoned financial expert, has joined the firm as th...

Xencor, Inc., a renowned clinical-stage biopharmaceutical company focused on developing engineered antibodies and cytokines for cancer and autoimmune diseases, recently presented exciting preclinical data from its multi...